Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
1 mg
5 mg
10 mg
1 mM
0.5505 mL
2.7523 mL
5.5045 mL
5 mM
0.1101 mL
0.5505 mL
1.1009 mL
10 mM
0.0550 mL
0.2752 mL
0.5505 mL
50 mM
0.0110 mL
0.0550 mL
0.1101 mL
Description
Dalbavancin (Zeven, BI 397, MDL 63397) is a lipoglycopeptide antibiotic that has bactericidal activity against Gram-positive bacteria including various staphylococci.
In vitro
Dalbavancin's mechanism of action involves the formation of a complex with the C-terminal d-alanyl-d-alanine of growing peptidoglycan chains, thereby inhibiting bacterial cell wall biosynthesis. In addition, dalbavancin appears to have the unique ability to dimerise and anchor its lipophilic side chain in the bacterial membranes. Dalbavancin possesses more potent in vitro bactericidal activity than vancomycin or teicoplanin against many resistant Gram-positive organisms.
In vivo
Dalbavancin has a half-life of 170-210 h in human. It exhibits linear, dose-dependent pharmacokinetics in healthy adults, following the administration of single intravenous doses of dalbavancin 140-1120 mg. Total protein binding of dalbavancin is concentration independent, reversible and estimated to be 93%. Animal studies regarding tissue distribution have demonstrated tissue concentrations reaching maximal levels within 24 h, with the highest concentrations in the liver and kidneys.
Ristomycin A aglycone, 5,31-dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-[2-deoxy-2-[(10-methyl-1-oxoundecyl)amino]-β-D-glucopyranuronosyl]-38-[[[3-(dimethylamino)propyl]amino]carbonyl]-42-O-α-D-mannopyranosyl-N15-methyl-
5,31-Dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-[2-deoxy-2-[(10-methyl-1-oxoundecyl)amino]-β-D-glucopyranuronosyl]-38-[[[3-(dimethylamino)propyl]amino]carbonyl]-42-O-α-D-mannopyranosyl-N15-methylristomycin A aglycone